| Literature DB >> 29896253 |
Yuting Liu1, Fengping Mu2, Lijuan Liu1, Chune Shan3.
Abstract
Changes of interleukin (IL)-1β, IL-6, IL-17 and tumor necrosis factor-α (TNF-α) in gingival crevicular fluid in patients with fixed orthodontic gingivitis after treatment with Kangfuxin solution were analyzed to explore the clinical effect of Kangfuxin solution in patients with orthodontic gingivitis. A total of 78 patients diagnosed with fixed orthodontic gingivitis in Weifang People's Hospital from January 2015 to March 2017 were selected. Thirty-nine patients were treated with gingival cleansing as control group, and the other 39 patients were treated with gingival cleansing plus spraying and sublingual administration with Kangfuxin solution as treatment group. The general data of patients were collected, and the changes of IL-1β, IL-6, IL-17 and TNF-α in gingival crevicular fluid were measured, the bleeding index (BI), probing depth (PD), swelling and pain grades were recorded, and the clinical curative effects were compared between the two groups. The curative effect in treatment group was better than that in control group (p<0.05). After treatment, gingival BI and PD in both groups were lower than those before treatment. The curative effect in treatment group was better than that in control group (p<0.05). The levels of gingival pain and swelling after treatment in treatment group were mainly in grade I. The levels of gingival pain and swelling after treatment in control group were mainly in grade II and III (p<0.05). After treatment, the effective rate of control group was 76.92% and that of treatment group was 97.44% (p<0.05). It was found that the levels of IL-6 and TNF-α in gingival crevicular fluid were positively correlated with PD. The use of Kangfuxin solution in the treatment of patients with orthodontic gingivitis can effectively reduce the levels of IL-1β, IL-6, IL-17 and TNF-α in gingival crevicular fluid, and improve the periodontal conditions and the effective rate of treatment.Entities:
Keywords: fixed orthodontic; gingivitis; interleukin-17; interleukin-1β; interleukin-6; tumor necrosis factor
Year: 2018 PMID: 29896253 PMCID: PMC5995036 DOI: 10.3892/etm.2018.6171
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparisons of general data between treatment and control group by Student's t-test.
| General data | Treatment group (n=39) | Control group (n=39) | P-value |
|---|---|---|---|
| Age (years) | 15.94±1.77 | 16.22±1.08 | 0.719 |
| Sex (male/female) | 20/19 | 21/18 | 0.908 |
| Course of gingivitis (months) | 5.99±0.87 | 6.32±1.01 | 0.779 |
| BMI (kg/m2) | 21.73±4.62 | 20.64±3.91 | 0.813 |
Comparison of levels of inflammatory factors before and after treatment between treatment and control group by Student's t-test.
| Groups | No. | Time | IL-1β (ng/l) | IL-17 (ng/ml) | IL-6 (ng/l) | TNF-α (pg/ml) |
|---|---|---|---|---|---|---|
| Control | 39 | Before treatment | 14.23±1.76 | 3.26±0.71 | 16.34±2.23 | 13.29±4.18 |
| After treatment | 10.97±1.78 | 1.87±0.33 | 10.41±1.16 | 9.45±1.44 | ||
| Treatment | 39 | Before treatment | 14.38±1.91 | 3.31±0.96 | 16.44±2.29 | 13.66±3.91 |
| After treatment | 8.79±1.83 | 0.97±0.42 | 8.16±1.68 | 7.08±1.16 |
P<0.05, compared with that before treatment, and p<0.05, compared with that after treatment in control group. IL, interleukin; TNF-α, tumor necrosis factor-α.
Comparison of periodontal conditions before and after treatment between treatment and control group by Student's t-test.
| Groups | No. | Time | BI | PD (mm) |
|---|---|---|---|---|
| Control | 39 | Before treatment | 3.93±0.41 | 4.79±0.45 |
| After treatment | 2.77±0.38 | 3.33±0.41 | ||
| Treatment | 39 | Before treatment | 3.89±0.37 | 4.81±0.49 |
| After treatment | 1.54±0.49 | 2.36±0.37 |
P<0.05, compared with that before treatment, and p<0.05, compared with that after treatment in control group. ΒI, bleeding index; PD, probing depth.
Comparison of swelling and pain levels after treatment between treatment and control group by ANOVA.
| Pain level (n, %) | Swelling level (n, %) | ||||||
|---|---|---|---|---|---|---|---|
| Groups | No. | Grade I | Grade II | Grade III | Grade I | Grade II | Grade III |
| Control | 39 | 13 (33.33) | 17 (43.59) | 9 (23.08) | 13 (33.33) | 16 (41.03) | 10 (25.64) |
| Treatment | 39 | 35 (89.74) | 3 (7.69) | 1 (2.56) | 36 (92.31) | 2 (5.13) | 1 (2.56) |
P<0.05, the difference is statistically significant.
Comparison of therapeutic effects between treatment and control group by ANOVA.
| Groups | No. | Markedly effective (n, %) | Improved (n, %) | Ineffective (n, %) | Effective (n, %) |
|---|---|---|---|---|---|
| Control | 39 | 17 (43.59) | 13 (33.33) | 9 (23.08) | 30 (76.92) |
| Treatment | 39 | 34 (87.18) | 4 (10.26) | 1 (2.56) | 38 (97.44) |
| P-value | 0.001 |
Figure 1.Correlation between IL-6 and PD. IL, interleukin; PD, probing depth.
Figure 2.Correlation between TNF-α and PD. TNF-α, tumor necrosis factor-α; PD, probing depth.